<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">Viral S-glycoprotein, TMPRSS2 and ACE-2 inhibition are important objectives of therapy and probably vaccine development [
 <xref ref-type="bibr" rid="CR39">39</xref>]. Subunit vaccines are commenced depending on the full-length S protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins [
 <xref ref-type="bibr" rid="CR2">2</xref>]. Using structure-based drug screening to detect SARS-CoV-2 protease blockers, macrolides (MAC) were believed to be effective for COVID-19 [
 <xref ref-type="bibr" rid="CR78">78</xref>].
</p>
